Celsion (CLSN) Announces Positive Data from First OVATION Study; One Complete Response Noted
Tweet Send to a Friend
Celsion Corporation (NASDAQ: CLSN) announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
